Top

International Journal of Colorectal Disease

Published in:

01-12-2011 | Original Article

Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer

Authors: Xiao-Gang Shen, Cun Wang, Yuan Li, Bin Zhou, Bin Xu, Lie Yang, Zong-Guang Zhou, Xiao-Feng Sun

Published in: International Journal of Colorectal Disease | Issue 12/2011

Abstract

Purpose

The aim of this study was to evaluate the prevalence and clinical significance of caspase-10 mRNA expression in stage II colorectal cancer.

Methods

Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) was used to analyze caspase-10 expression in cancer tissue and corresponding normal mucosa from 120 patients with stage II colorectal cancer. Variables were analyzed by Chi-square test or Fisher’s exact test. Survival was evaluated with method of Kaplan–Meier. Multivariate analysis was performed with Cox’s proportional hazards model.

Results

The expression of caspase-10 mRNA was found to be downregulated in cancer tissue compared to normal mucosa (P = 0.001). Poorly differentiated cancer showed lower mRNA expression than cancer with greater differentiation (P = 0.031). Univariate survival curves, estimated using the method of Kaplan–Meier, defined a significant association between caspase-10 expression and both overall survival (P = 0.012) and disease-free survival (P = 0.021). A multivariate analysis, performed by Cox’s proportional hazards regression model, confirmed that a low caspase-10 expression was the only significant factor to predict poor prognosis in patients with stage II colorectal cancer.

Conclusion

Our data indicate that caspase-10 expression, measured by quantitative real-time RT-PCR, is a possible prognostic factor in patients with stage II colorectal cancer.

Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRef

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef

Sobin LH, Wittekin CH (1999) UICC TNM classification of malignant tumors, 5th edn. Wiley-Liss, New York

NIH Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264(11):1444–1450CrossRef

Riethmuller G, Schneider-Gadicke E, Schlimok G et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343:1177–1183PubMedCrossRef

Moertel CG, Fleming TR, Macdonald JS et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMed

Dube S, Heyen F, Jenicek M (1997) Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 40:35–41PubMedCrossRef

O’Connell MJ, Mailliard JA, Kahn MJ et al (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246–250PubMed

Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349–1355PubMed

10.

Glimelius B, Dahl O, Cedermark B et al (2005) Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 44:904–912PubMed

11.

Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB (2002) Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20:3999–4005PubMedCrossRef

12.

Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806PubMedCrossRef

13.

Sjostrom J, Bergh J (2001) How apoptosis is regulated, and what goes wrong in cancer. BMJ 322:1538–1539PubMedCrossRef

14.

Wong BC, Zhu GH, Lam SK (1999) Aspirin induced apoptosis in gastric cancer cells. Biomed Pharmacother 53:315–318PubMedCrossRef

15.

Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281:1312–1316PubMedCrossRef

16.

Ghavami S, Hashemi M, Ande SR et al (2009) Apoptosis and cancer: mutations within caspase genes. J Med Genet 46:497–510PubMedCrossRef

17.

Shen XG, Wang C, Li Y et al (2010) Downregulation of caspase-9 is a frequent event in patients with stage II colorectal cancer and correlates with poor clinical outcome. Colorectal Dis 12:1213–1218PubMedCrossRef

18.

Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF (2006) Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol 290:G1067–G1074PubMedCrossRef

19.

Mygind T, Birkelund S, Birkebaek NH, Ostergaard L, Jensen JS, Christiansen G (2002) Determination of PCR efficiency in chelex-100 purified clinical samples and comparison of real-time quantitative PCR and conventional PCR for detection of Chlamydia pneumoniae. BMC Microbiol 2:17PubMedCrossRef

20.

Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCrossRef

21.

Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36PubMedCrossRef

22.

Shibata D, Reale MA, Lavin P et al (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727–1732PubMedCrossRef

23.

Zaniboni A, Labianca R (2004) Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol 15:1310–1318PubMedCrossRef

24.

Comoglio PM, Boccaccio C (2001) Scatter factors and invasive growth. Semin Cancer Biol 11:153–165PubMedCrossRef

25.

Wong CW, Lee A, Shientag L et al (2001) Apoptosis: an early event in metastatic inefficiency. Cancer Res 61:333–338PubMed

26.

Fernandes-Alnemri T, Armstrong RC, Krebs J et al (1996) In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci USA 93:7464–7469PubMedCrossRef

27.

Grenet J, Teitz T, Wei T, Valentine V, Kidd VJ (1999) Structure and chromosome localization of the human CASP8 gene. Gene 226:225–232PubMedCrossRef

28.

Xu B, Zhou ZG, Li Y et al (2008) Clinicopathological significance of caspase-8 and caspase-10 expression in rectal cancer. Oncology 74:229–236PubMedCrossRef

29.

Engels IH, Totzke G, Fischer U, Schulze-Osthoff K, Janicke RU (2005) Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Cell Biol 25:2808–2818PubMedCrossRef

30.

Shin MS, Kim HS, Kang CS et al (2002) Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 99:4094–4099PubMedCrossRef

31.

Park WS, Lee JH, Shin MS et al (2002) Inactivating mutations of the caspase-10 gene in gastric cancer. Oncogene 21:2919–2925PubMedCrossRef

32.

Kischkel FC, Lawrence DA, Tinel A et al (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276:46639–46646PubMedCrossRef

33.

Fong PY, Xue WC, Ngan HY et al (2006) Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study. J Clin Pathol 59:179–183PubMedCrossRef

34.

Harada K, Toyooka S, Shivapurkar N et al (2002) Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62:5897–5901PubMed

35.

Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ (2001) Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 98:13884–13888PubMedCrossRef

36.

Li J, Chen P, Sinogeeva N et al (2002) Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem 277:49504–49510PubMedCrossRef

37.

Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N (2000) Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 60:4315–4519PubMed

38.

Kolenko V, Uzzo RG, Bukowski R et al (1999) Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res 59:2838–2842PubMed

39.

Giotakis J, Gomatos IP, Alevizos L et al (2010) Bax, cytochrome c, and caspase-8 staining in parotid cancer patients: markers of susceptibility in radiotherapy? Otolaryngol Head Neck Surg 142:605–611PubMedCrossRef

40.

Pingoud-Meier C, Lang D, Janss AJ et al (2003) Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 9:6401–6409PubMed

41.

Fulda S, Poremba C, Berwanger B et al (2006) Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 66:10016–10023PubMedCrossRef

Title: Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer
Authors: Xiao-Gang Shen
Cun Wang
Yuan Li
Bin Zhou
Bin Xu
Lie Yang
Zong-Guang Zhou
Xiao-Feng Sun
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 12/2011
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-011-1239-z

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2011

Clinical usefulness of pit patterns for detecting colonic lesions requiring surgical treatment

Risk of anastomotic leakage with use of NSAIDs after gastrointestinal surgery

Severe immunosuppression in inflammatory bowel disease: opening the floodgates to opportunists?

Sacral neuromodulation for the management of severe constipation: development of a constipation treatment protocol

Perioperative quality of care is modulated by process management with clinical pathways for fast-track surgery of the colon

Colorectal cancer following liver transplantation